Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H29FN2O4 |
| Molecular Weight | 428.4965 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=CC=C1OCCCN2CCC(CC2)C3=NOC4=CC(F)=CC=C34)[C@H](C)O
InChI
InChIKey=SBKZGLWZGZQVHA-INIZCTEOSA-N
InChI=1S/C24H29FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-17,28H,3,8-13H2,1-2H3/t16-/m0/s1
P-88-8991, (-)- is a metabolite of Iloperidone. It has functional affinity for noradrenergic, dopaminergic and serotoninergic receptors. Humans produce only one enantiomer stereospecifically following administration of Iloperidone. Preclinical studies revealed that P-88-8991, (-)- might be useful for the treatment of psychotic disorders such as schizophrenia and bipolar disorders.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094251 |
8.9 null [pKi] | ||
Target ID: CHEMBL1916 |
7.8 null [pKi] | ||
Target ID: CHEMBL322 |
8.9 null [pKi] | ||
Target ID: CHEMBL3372 |
8.1 null [pKi] | ||
Target ID: CHEMBL217 |
7.4 null [pKi] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7SV1ZOG031
Created by
admin on Sat Dec 16 01:45:52 GMT 2023 , Edited by admin on Sat Dec 16 01:45:52 GMT 2023
|
PRIMARY | |||
|
10365268
Created by
admin on Sat Dec 16 01:45:52 GMT 2023 , Edited by admin on Sat Dec 16 01:45:52 GMT 2023
|
PRIMARY | |||
|
501373-88-2
Created by
admin on Sat Dec 16 01:45:52 GMT 2023 , Edited by admin on Sat Dec 16 01:45:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE)
